PBX3 promotes migration and invasion of colorectal cancer cells via activation of MAPK/ERK signaling pathway

Table 1 Relationship between pre-B-cell leukemia homeobox 3 expression and pathological features of colorectal cancer n (%)

Variable	Case	PBX3 expression1 Median (range)	P value2
Sex
Male	63 (56.8)	0.590 (0.00-14.16)	0.527
Female	48 (43.2)	0.690 (0.04-12.84)
Age
≤ 60	51(45.9)	1.010 (0.02-14.16)	0.425
> 60	60 (54.1)	0.945 (0.00-12.18)
Venous invasion
Absent	69 (62.2)	0.870 (0.00-14.16)	0.557
Present	42 (37.8)	1.095 (0.07-9.83)
Histological type
Adenocarcinoma	108 (97.3)	0.995 (0.00-14.16)	0.874
Mucinous adenocarcinoma	3 (2.7)	1.620 (0.20-0.67)
Differentiation3
Poor	16 (14.8)	0.865 (0.12-12.84)	0.714
Moderate	75 (69.4)	0.990 (0.02-14.16)
Well	17 (15.7)	1.080 (0.00-8.19)
Tumor stage
1-2	8 (7.2)	0.360 (0.02-2.84)	0.211
3	85 (76.6)	1.010 (0.00-14.16)
4	18 (16.2)	1.075 (0.10-9.83)
Lymph node metastasis
Negative	41 (36.9)	0.7600 (0.02-12.84)	0.0199a
Positive	70 (63.1)	1.3300 (0.0-14.16)
Metastasis stage
M0	53 (47.7)	0.790 (0.02-6.44)	0.0385a
M1	58 (52.3)	1.230 (0.00-14.16)
TNM stage
I-II	32 (28.8)	0.775 (0.02-5.50)	0.0293a
III-IV	79 (71.2)	1.220 (0.00-14.16)
Metastasis
Absent	41 (36.9)	0.550 (0.02-5.90)	0.0405a
Present (SM and MM)	70 (63.1)	1.200 (0.00-14.16)

¹Relative PBX3 expression was calculated by 2^-ΔΔCt;

²Significant differences were evaluated by Mann-Whitney test for two groups and Kruskal-Wallis test for more groups;

³Degree of differentiation for adenocarcinoma.

^aP < 0.05 vs control. SM: Synchronous metastasis; MM: Metachronous metastasis.